Sanofi SA (SASY)

97.10 +1.26 (+1.31%)
Close EUR Disclaimer

Sanofi SA Company Profile

Equity Type
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Contact Information
Paris,75017 France
33 1 53 77 40 00
33 1 53 77 43 03
Top Executives
Fabienne Lecorvaisier 59 2013 Independent Director
Jean-François Dehecq 81 1982 Honorary Chairman
Patrick Kron 68 2014 Independent Director
Paul Hudson 54 2019 CEO & Director
Serge Weinberg 70 2009 Chairman of the Board
Gilles Schnepp 63 2021 Independent Director
Diane D. Souza 70 2016 Independent Director
Rachel Duan 52 2020 Independent Director
Lise Kingo 61 2020 Independent Director
Ceng-Yann Tran 57 2021 Employee Representative Director
Thomas C. Sudhof 67 2016 Independent Director
Emile Voest 0 2022 Independent Director
Christophe Babule 57 2019 Director
Carole Ferrand 52 2022 Independent Director
Wolfgang Laux 54 2021 Employee Representative Director
Barbara Lavernos 54 2021 Director
Antoine Yver 64 2022 Independent Director
Frederic Oudea 59 2022 Non-Voting Member of the Board
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles